Coya Therapeutics, Inc.'s Quiet Period Set To End on February 7th (NASDAQ:COYA)
Coya Therapeutics, Inc.'s Quiet Period Set To End on February 7th (NASDAQ:COYA)
Coya Therapeutics' (NASDAQ:COYA – Get Rating) quiet period is set to end on Tuesday, February 7th. Coya Therapeutics had issued 3,050,000 shares in its IPO on December 29th. The total size of the offering was $15,250,000 based on an initial share price of $5.00. During Coya Therapeutics' quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Coya Therapeutics（纳斯达克股票代码：COYA — Get Rating）的静默期定于2月7日星期二结束。Coya Therapeutics在12月29日的首次公开募股中发行了305万股股票。按5.00美元的初始股价计算，此次发行的总规模为15250,000美元。在Coya Therapeutics的平静期，由于美国证券交易委员会发布的规定，参与首次公开募股的内部人士和承销商被限制为该公司发布任何研究报告。在公司的平静期结束后，担任承销商的经纪公司很可能会开始对该公司进行研究报道。
Analyst Upgrades and Downgrades
分析师升级和降级
Separately, Chardan Capital initiated coverage on shares of Coya Therapeutics in a report on Thursday, January 26th. They issued a "buy" rating and a $9.00 price target on the stock.
另外，Chardan Capital在1月26日星期四的一份报告中开始报道Coya Therapeutics的股票。他们对该股发布了 “买入” 评级和9.00美元的目标价。
Coya Therapeutics Stock Down 4.2 %
Coya Therapeutics 股票下跌 4.2
NASDAQ COYA opened at $4.35 on Tuesday. Coya Therapeutics has a 12 month low of $4.26 and a 12 month high of $5.67.
纳斯达克COYA周二开盘价为4.35美元。Coya Therapeutics创下12个月低点4.26美元，12个月高点为5.67美元。
About Coya Therapeutics
关于 Coya Therapeut
Coya Therapeutics Inc is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Coya Therapeutics Inc是一家处于临床阶段的生物技术公司。它参与开发专有疗法，侧重于调节性T细胞的生物学和潜在治疗优势，以靶向全身性炎症和神经炎症。该公司的治疗平台包括增强调节性TREG的生物制剂、TREG衍生的外泌体和自体调节性Treg细胞疗法。
See Also
另见
- Get a free copy of the StockNews.com research report on Coya Therapeutics (COYA)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 免费获取 StockNews.com 关于 Coya Therapeutics (COYA) 的研究报告
- 为什么黄金现在可以成为你投资组合的闪亮补充
- SoFi Technologies 打破收益但要当心美联储
- 买入 Colgate-Palmolive 的 Dip
- Mullen Automotive 正在疯狂招聘，那可能意味着什么？
- InterDigital 上调了收益预期
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Coya Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Coya Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。